Acepodia, Inc. (6976.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Taiwan
Price
11.95 TWD
Market cap
6.96 bn TWD
P/E (2025)
–
P/S (2025)
37,604.15
Dividend yield
0.00 %
Net margin
-407,784.32 %
Return on equity (ROE)
-13.92 %
Return on assets (ROA)
-12.93 %
Acepodia, Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 427,000.00 TWD | 185,000.00 TWD |
| Gross profit | 278,000.00 TWD | 121,000.00 TWD |
| Operating income | -757.90 m TWD | -969.20 m TWD |
| EBIT | -466.50 m TWD | -757.27 m TWD |
| Net income | -496.75 m TWD | -754.40 m TWD |
| Diluted EPS – continuing operations | -0.87 TWD | -1.30 TWD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Acepodia, Inc.
Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; The company is based in Grand Cayman, the Cayman Islands.
More stocks
- AC Immune Ltd (ACIU)
- P2 Gold Inc (PGLD.V)
- Eco Atlantic Oil & Gas Ltd (EOG.V)
- Josef Manner & Comp. AG (MAN.VI)
- Advanced Information Technology Public Company Limited (AIT.BK)
- WEWARDS, INC. (WEWA)
- Mildef Crete (3213.TWO)
- Cosmos Group Holdings Inc. (COSG)
- Hung Sheng Construction Ltd (2534.TW)
- Aprilbio Co. Ltd. (397030.KQ)
- Inhibikase Therapeutics, Inc. (IKT)
- Infinite Finance Co. Ltd. (6958.TW)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.